Citigroup Cuts Ascendis Pharma A (ASND) Price Target to $330
Key Points
- Citigroup adjusted its price target for Ascendis Pharma A from $360 to $330 on October 26, 2026.
- Citigroup's $330 price target implies 35.60% upside from Ascendis Pharma A's ($ASND) current $243.37 share price.
- The stock recently traded at $243.37, which is about 0.9% below its closing price of $245.63 on the same day.
- Ascendis Pharma has a market cap of approximately $16 billion and a strong revenue growth rate of 114.7% year-over-year.
Get Ascendis Pharma A text alerts
We text you when insiders, Congress, analysts or big funds move on $ASND.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Ascendis Pharma A alert may contain errors. Disclosures
On October 26, 2026, Citigroup lowered its price target on Ascendis Pharma A (ASND) from $360 to $330 while maintaining a Buy rating. This adjustment comes as the company continues to develop innovative therapies for unmet medical needs.
The lowered target reflects Citigroup's ongoing analysis of Ascendis Pharma's performance and market conditions. The stock closed at $245.63 on the same day, while the recent trading price was $243.37, indicating a slight decline of about 0.9% since the close. Despite this, the stock remains above its 50-day and 200-day moving averages, showing some stability in the current market environment.
ASND
Ascendis Pharma A
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Ascendis Pharma A
Massachusetts Financial Services Co. grew its holdings by 14,699 shares, ending with 1,875,301 shares worth about $460.6 million. Capital International Investors added 29,774 shares, bringing its total to 1,988,614 shares valued at approximately $488.5 million. In contrast, Westfield Capital Management Co LP reduced its stake by 15,404 shares, now holding 4,798,267 shares valued at around $1.18 billion. Artisan Partners Limited Partnership trimmed its position by 596,322 shares, ending with 2,634,024 shares worth about $647 million.
Ascendis Pharma A Stock Up 0.2%
Ascendis Pharma's stock is currently trading at $243.37, which is about 13.7% below its 52-week high of $282.15. The recent price is also about 29.4% above its 52-week low of $188.07. This positioning suggests that while the stock has seen some volatility, it is still performing relatively well compared to its historical range.
$ASND price target
Ascendis Pharma A daily closes and this analyst's $330 target. Not advice.
Recent Earnings
In its latest earnings report, Ascendis Pharma posted a trailing twelve-month revenue of approximately $1.05 billion, with an impressive year-over-year revenue growth rate of 114.7%. The company reported earnings per share (EPS) of $13.05, reflecting strong profitability in its operations. The next earnings date is expected to be in November 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
3 target raises vs 1 cuts.
-
EPS & revenue
EPS missed estimates by 471.1%. Revenue missed estimates by 9.0%.
-
Profit surprise
EBITDA missed by 9 percent. Operating income missed by 8 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
3 target raises, 1 target cut.
-
Earnings quality
Gross margin up 8.7 points. Operating margin up 113.3 points. Negative free cash flow.
Earnings Call Summary
Ascendis reported first quarter revenue of about $251 million, down slightly from the $276 million consensus expected, but beat earnings expectations at $0.32 per share versus $0.21 expected. YORVIPATH contributed $197 million in revenue but was hit by about $15 million in one-time headwinds. YUVIWEL, their new hypochondroplasia treatment approved in February, saw about 60 children prescribed in just four to five weeks after launch, showing strong unmet need. The company is now profitable with a 22 percent non-IFRS operating margin and plans to give full-year guidance after the next quarter.
Guidance Management did not provide full year revenue or earnings guidance. Instead, they said they will give updated 2026 guidance after Q2 results. They expect strong sequential growth in YORVIPATH in Q2 after one-time disruptions reversed. YUVIWEL launch is tracking much stronger than hoped.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Insider Buying and Selling at Ascendis Pharma A
Several insiders have made transactions recently. Chief Financial Officer Scott Thomas Smith bought 100 shares at $219 each on June 2, 2026, totaling $21,900. Director Jean-Jacques Bienaime purchased 2,000 shares on August 14, 2026, valued at approximately $492,654. On the other hand, Director Lars Holtug sold 236 shares at $264.13 each on September 2, 2026, totaling about $62,335, while Officer Mads Bodenhoff sold 3,000 shares at $270.19 on September 8, 2026, for a total of $810,570.
Analysts Set New Price Targets
On October 26, 2026, Citigroup maintained its Buy rating on Ascendis Pharma while lowering its price target to $330 from $360. Other firms have also recently updated their targets. For instance, Morgan Stanley kept an Overweight rating with a target of $273, while Oppenheimer maintained an Outperform rating with a target of $312. The average target price among analysts is currently around $307.64 based on 21 opinions, indicating a generally positive outlook despite Citigroup's adjustment.
About Ascendis Pharma A
Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark. It focuses on developing TransCon-based therapies to address unmet medical needs in the healthcare sector. The company offers products like SKYTROFA for growth hormone deficiency in children and YORVIPATH for chronic hypoparathyroidism in adults.
Bottom Line
Investors should keep an eye on Ascendis Pharma's upcoming earnings report in November 2026, as well as any further analyst updates. Citigroup's recent price target change highlights the need for market participants to stay informed about the company's performance amid evolving market conditions.
Related Filing Alerts
Source: Citigroup's rating change on $ASND (Oct 26, 2026). Written by software, not financial advice. How we make alerts